XML 33 R2.htm IDEA: XBRL DOCUMENT v3.25.2
Consolidated Balance Sheets - USD ($)
Jun. 30, 2025
Jun. 30, 2024
Current assets    
Cash and cash equivalents $ 1,019,909 $ 6,304,098
Accounts receivable, net 594,614 429,704
Inventories, net 635,215 777,537
Research and development tax incentive receivable 734,408 525,332
Assets held for sale 327,500
Other current assets 826,976 497,572
Total current assets 4,138,622 8,534,243
Property and equipment, net 251,325 565,850
Operating lease right-of-use assets 69,520 306,744
Intangibles, net 3,790,319 4,372,026
Total assets 8,249,786 13,778,863
Current liabilities    
Accounts payable and accrued expenses 4,534,246 1,704,568
Current portion of operating lease liabilities 84,659 274,834
Deferred grant income 2,486,668
Current employee benefit liabilities 534,990 469,381
Notes payable 197,146 515,282
Total current liabilities 5,351,041 5,450,733
Employee benefit liabilities, less current portion 84,921 63,615
Operating lease liabilities, less current portion 81,324
Total liabilities 5,435,962 5,595,672
Commitments and contingencies (Note 16)
Shareholders’ equity    
Common stock, $0.01 par value, 100,000,000 shares authorized, 7,323,377 and 7,323,261 shares issued and outstanding, as of June 30, 2025, respectively; 3,456,116 and 3,456,000 shares issued and outstanding, as of June 30, 2024 respectively 73,230 34,557
Treasury stock, at cost, 116 shares as of June 30, 2025 and 2024 (1) (1)
Additional paid-in capital 65,783,916 60,971,740
Accumulated deficit (62,533,065) (51,964,332)
Accumulated other comprehensive loss (327,944) (712,614)
Total consolidated Intelligent Bio Solutions Inc. equity 2,996,136 8,329,350
Non-controlling interest (182,312) (146,159)
Total shareholders’ equity 2,813,824 8,183,191
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $ 8,249,786 $ 13,778,863